FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1700 November 25, 1999 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Even if women acknowledge the perinatal risks of cigarette smoking and wish to quit the habit, many women continue to smoke after realizing that they have conceived.¹ The transdermal nicotine patch, when combined with counseling, is an effective method of nicotine replacement.² However, nicotine has been shown to be teratogenic in animal studies, and it is categorized by the Food and Drug Administration at risk level D, which implies substantial risk to the fetus.^3,4 This has led clinicians and pharmaceutical companies to hesitate and largely to ignore the potential opportunity offered by the transdermal nicotine patch for . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Somm, E., Schwitzgebel, V. M., Vauthay, D. M., Camm, E. J., Chen, C. Y., Giacobino, J.-P., Sizonenko, S. V., Aubert, M. L., Huppi, P. S. (2008). Prenatal Nicotine Exposure Alters Early Pancreatic Islet and Adipose Tissue Development with Consequences on the Control of Body Weight and Glucose Metabolism Later in Life. Endocrinology 149: 6289-6299 [Abstract] [Full Text]